Unknown

Dataset Information

0

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.


ABSTRACT: Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4(+) T cell response. The individual contribution of these adaptive immune responses to protection from infection remains unknown. Here, we found that prophylactic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with humanized livers from i.v.- and mosquito bite–delivered P. falciparum sporozoite challenge. Titers of anti-CSP that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when reaching or exceeding a critical plasma concentration.

SUBMITTER: Foquet L 

PROVIDER: S-EPMC3871238 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.

Foquet Lander L   Hermsen Cornelus C CC   van Gemert Geert-Jan GJ   Van Braeckel Eva E   Weening Karin E KE   Sauerwein Robert R   Meuleman Philip P   Leroux-Roels Geert G  

The Journal of clinical investigation 20140101 1


Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4(+) T cell re  ...[more]

Similar Datasets

| S-EPMC6698827 | biostudies-literature
| S-EPMC8675929 | biostudies-literature
| S-EPMC7970865 | biostudies-literature
| S-EPMC9395511 | biostudies-literature
| S-EPMC8447852 | biostudies-literature
| S-EPMC7079517 | biostudies-literature
| S-EPMC4081809 | biostudies-literature
| S-EPMC257683 | biostudies-other
| S-EPMC2785382 | biostudies-literature
| S-EPMC3741388 | biostudies-literature